Advertisement

Topics

Albireo AB Company Profile

17:51 EDT 26th September 2017 | BioPortfolio

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfill unmet medical needs in the gastrointestinal (GI) area. The Albireo team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities. Albireo was created as a spin out of AstraZeneca and was based on a platform of clinical and preclinical GI programs emanating from within AstraZeneca. Albireo has raised $40m in a Series A financing round from leading healthcare investors including Nomura Phase4 ventures, TPG Biotech, TVM Capital and Scottish Widows Partnership.


News Articles [26 Associated News Articles listed on BioPortfolio]

Company Spotlight: Albireo Pharma

LONDON (dpa-AFX) - Shares of Albireo Pharma Inc. (ALBO) are up nearly 18% over the last 4 trading days. Albireo Pharma is a clinical-stage company focused on developing therapies for pediatric liv...

Albireo: Millionen von Goldman-Sachs-Manager!

Unsere Biotech-Entdeckung Albireo Pharma (WKN: A2DF99) entwickelt sich weiterhin glänzend, auch wenn die Höchstkurse von über 30 USD aus dem November derzeit ein gutes Stück entfernt erscheinen. D...

Biotech-Roundup: Albireo, OncoGenex, Ritter, Palatin, Paion

Erneute Kursgewinne mit Ansage: Albireo Pharma (WKN: A2DF99) und OncoGenex (WKN: A0Q8G8) können in dieser Woche ihre Anleger begeistern. Bei Paion (WKN: A0B65S) ist die Luft wie erwartet erstmal ra.....

Albireo to initiate A4250’s Phase III clinical programme to treat PFIC

Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepati...

Albireo nets $42.4mm in public stock sale

Albireo Pharma Inc. (primarily develops liver disease treatments; also has GI projects) netted $42.4mm through a public offering of 2.2mm common shares at $20.50. Proceeds are earmarked for Phase III ...

Albireo nets $48.7mm in public stock sale

Albireo Pharma Inc. (primarily develops liver disease treatments; also has GI projects) netted $48.7mm through a public offering of 2.5mm common shares (including the overallotment) at $20.50. Proceed...

Albireo raises $45.1M in follow-on

Albireo to Present at Investor Conferences in September

BOSTON, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Albireo AB

Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfill unmet medical needs in the gastrointestinal (GI) area. The Albir...

More Information about "Albireo AB" on BioPortfolio

We have published hundreds of Albireo AB news stories on BioPortfolio along with dozens of Albireo AB Clinical Trials and PubMed Articles about Albireo AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Albireo AB Companies in our database. You can also find out about relevant Albireo AB Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record